Literature DB >> 25181580

Pathogenesis and classification of intrahepatic cholangiocarcinoma: different characters of perihilar large duct type versus peripheral small duct type.

Shinichi Aishima1, Yoshinao Oda.   

Abstract

Intrahepatic cholangiocarcinomas (ICCs) are made up of heterogenous carcinomas arising from different anatomical sites of the liver. Two types of candidate stem/progenitor cells of the biliary tree are postulated to exist at the peribiliary glands for large bile ducts and at the canals of Hering for small ducts and hepatocytes. According to the recent observations, ICCs can be subclassified into two types: tumors involving the large bile ducts comparable in size to the intrahepatic second branches and composed of a tubular or papillary component with tall columnar epithelium, and tumors involving the smaller duct than segmental branches and composed of small tubules with cuboidal epithelium. Perihilar large duct type ICCs can be interpreted as arising from large bile duct type ICCs, and peripheral small duct type ICCs may arise from small bile duct type or ductular type ICCs. Chronic biliary inflammation induces neoplastic change of the large bile ducts and thereby progression to the perihilar large duct type ICC, which can be grossly classified into periductal filtrating type ICC and intraductal growth type ICC, while chronic hepatitis or cirrhosis induces mass-forming peripheral small duct type ICC. The different morphological and molecular features, including stromal components and tumor vasculature, support the hypothesis that perihilar large duct type ICCs and peripheral small duct type ICCs arise from different backgrounds, have different carcinogenetic pathways, and exhibit different biologic behaviors.
© 2014 Japanese Society of Hepato-Biliary-Pancreatic Surgery.

Entities:  

Keywords:  Cholangiocarcinoma; Cholangiolocellular carcinoma; Perihilar; Peripheral

Mesh:

Year:  2014        PMID: 25181580     DOI: 10.1002/jhbp.154

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Sci        ISSN: 1868-6974            Impact factor:   7.027


  54 in total

1.  Mass-forming intrahepatic cholangiocarcinoma: Enhancement patterns in the arterial phase of dynamic hepatic CT - Correlation with clinicopathological findings.

Authors:  Nobuhiro Fujita; Yoshiki Asayama; Akihiro Nishie; Kousei Ishigami; Yasuhiro Ushijima; Yukihisa Takayama; Daisuke Okamoto; Koichiro Moirta; Ken Shirabe; Shinichi Aishima; Huanlin Wang; Yoshinao Oda; Hiroshi Honda
Journal:  Eur Radiol       Date:  2016-05-10       Impact factor: 5.315

2.  A proposal of imaging classification of intrahepatic mass-forming cholangiocarcinoma into ductal and parenchymal types: clinicopathologic significance.

Authors:  Hyungjin Rhee; Myeong-Jin Kim; Young Nyun Park; Chansik An
Journal:  Eur Radiol       Date:  2018-12-17       Impact factor: 5.315

Review 3.  Cholangiocarcinoma: Classification, Histopathology and Molecular Carcinogenesis.

Authors:  Gábor Lendvai; Tímea Szekerczés; Idikó Illyés; Réka Dóra; Endre Kontsek; Alíz Gógl; András Kiss; Klára Werling; Ilona Kovalszky; Zsuzsa Schaff; Katalin Borka
Journal:  Pathol Oncol Res       Date:  2018-11-17       Impact factor: 3.201

4.  Apical membrane expression of distinct sulfated glycans represents a novel marker of cholangiolocellular carcinoma.

Authors:  Hitomi Hoshino; Makoto Ohta; Makoto Ito; Kenji Uchimura; Yasuhiro Sakai; Takeshi Uehara; Shulin Low; Mana Fukushima; Motohiro Kobayashi
Journal:  Lab Invest       Date:  2016-10-17       Impact factor: 5.662

5.  Low Incidence of Lymph Node Metastasis After Resection of Hepatitis Virus-Related Intrahepatic Cholangiocarcinoma.

Authors:  Hiroya Iida; Masaki Kaibori; Shogo Tanaka; Shigekazu Takemura; Hiroshi Wada; Fumitoshi Hirokawa; Takuya Nakai; Michihiro Hayashi; Hidetoshi Eguchi; Shoji Kubo
Journal:  World J Surg       Date:  2017-04       Impact factor: 3.352

6.  Impact of tumor localization on the outcomes of surgery for an intrahepatic cholangiocarcinoma.

Authors:  Tatsuya Orimo; Toshiya Kamiyama; Tomoko Mitsuhashi; Hirofumi Kamachi; Hideki Yokoo; Kenji Wakayama; Shingo Shimada; Akihisa Nagatsu; Akinobu Taketomi
Journal:  J Gastroenterol       Date:  2018-05-02       Impact factor: 7.527

7.  Prognostic significance of contrast-enhanced CT attenuation value in extrahepatic cholangiocarcinoma.

Authors:  Yoshiki Asayama; Akihiro Nishie; Kousei Ishigami; Yasuhiro Ushijima; Yukihisa Takayama; Daisuke Okamoto; Nobuhiro Fujita; Takao Ohtsuka; Tomoharu Yoshizumi; Shinichi Aishima; Yoshinao Oda; Hiroshi Honda
Journal:  Eur Radiol       Date:  2016-10-17       Impact factor: 5.315

Review 8.  Early detection of intrahepatic cholangiocarcinoma.

Authors:  Mami Hamaoka; Kazuto Kozaka; Osamu Matsui; Takahiro Komori; Takashi Matsubara; Norihide Yoneda; Kotaro Yoshida; Dai Inoue; Azusa Kitao; Wataru Koda; Toshifumi Gabata; Satoshi Kobayashi
Journal:  Jpn J Radiol       Date:  2019-08-01       Impact factor: 2.374

9.  Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).

Authors:  Jesus M Banales; Vincenzo Cardinale; Guido Carpino; Marco Marzioni; Jesper B Andersen; Pietro Invernizzi; Guro E Lind; Trine Folseraas; Stuart J Forbes; Laura Fouassier; Andreas Geier; Diego F Calvisi; Joachim C Mertens; Michael Trauner; Antonio Benedetti; Luca Maroni; Javier Vaquero; Rocio I R Macias; Chiara Raggi; Maria J Perugorria; Eugenio Gaudio; Kirsten M Boberg; Jose J G Marin; Domenico Alvaro
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-04-20       Impact factor: 46.802

10.  EVI1 expression is associated with aggressive behavior in intrahepatic cholangiocarcinoma.

Authors:  Mariko Tanaka; Junji Shibahara; Shumpei Ishikawa; Tetsuo Ushiku; Teppei Morikawa; Aya Shinozaki-Ushiku; Akimasa Hayashi; Kento Misumi; Atsushi Tanaka; Hiroto Katoh; Kei Sakuma; Takashi Kokudo; Yoshinori Inagaki; Junichi Arita; Yoshihiro Sakamoto; Kiyoshi Hasegawa; Masashi Fukayama
Journal:  Virchows Arch       Date:  2018-10-23       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.